Discovery could lead to improved chronic worm treatment


Monday, 31 July, 2023

Discovery could lead to improved chronic worm treatment

Monash University researchers have uncovered why some intestinal worm infections become chronic in animal models, which could eventually lead to human vaccines and improved treatments.

Parasitic worms, also called helminths, are highly prevalent in developing countries such as sub-Saharan Africa, South America and some tropical countries in Asia. In Australia, they can be a problem in First Nations communities.

Some people can fight off the parasites due to effective immune responses. Some people who fail to develop effective immune responses suffer with a long-lasting chronic infection.

The new study reveals a protective immune feature may be lacking in people who are chronically infected. The researchers discovered that a group of immune cells called T follicular helper (TFH) cells behaved very differently at cellular and molecular levels during acute, resolving and chronic helminth infection. This meant that in some models the cells protected against chronic illness but in others they didn’t.

First author Dr Aidil Zaini said blocking the TFH response impaired worm clearance and promoted chronic infection, so the key was to develop ways to facilitate the protective mechanism.

He said humans also had varying immune responses, so further investigation could develop ways of protecting those prone to chronic disease.

“Our findings provide a proof of concept that harnessing the protective features of these immune cells may pave the way for the development of human vaccines and new drugs against helminths,” Zaini explained.

“Although conventional deworming drugs can help clear the parasites, they fail to provide long-term protection and are likely to be less effective due to the development of resistance against these drugs by the parasites.”

Zaini said the results were promising and warranted further investigation. He said the ultimate therapeutic goal was to develop effective vaccines against parasitic helminths in humans, which were not yet available.

“Our discovery contributes to the growing body of literature on the protective immune features during helminth infection,” Professor Colby Zaph said.

“This knowledge can be further explored to facilitate the development of long-term immune interventions for helminth infections, as well as diseases such as allergy. Interestingly, our immune system evolves into developing a similar type of immune response during both helminth infection and allergic responses.”

Zaph said, “In addition, the fundamental discovery that TFH cells that are responding to the same infection can differ so significantly at the molecular level highlights the functional diversity that exists in our immune system, which hopefully can be exploited to manipulate immune responses in the future.”

Co-senior author Professor Kim Good-Jacobson said that parasitic worm infections continued to be a large global health burden. “Now that we can identify the tipping point between effective clearance of worms and a chronic infection taking hold, we hope this work will lead to new ways to prevent or treat these diseases,” Good-Jacobson said.

The paper, Heterogeneous Tfh cell populations that develop during enteric helminth infection predict the quality of type 2 protective response, has been published in Mucosal Immunology.

Image caption: Immunofluorescence images showing a chronically helminth infected lymph node A or resistant lymph node B. Image courtesy of Monash University. For a clearer image, click here.

Related News

Targeted prostate cancer treatment hopes to minimise side effects

The Icon Cancer Centres in Victoria are using focal low dose rate (LDR) brachytherapy to provide...

Plasma treatment for healing chronic wounds

More than 420,000 Australians suffer from a chronic wound each year, costing the health and aged...

Digital therapy reduces distress in long-term conditions

People living with long-term conditions who received the therapist-guided digital program have...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd